You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Obtenez les dernières mises à jour ou faites une autoévaluation.

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Lignes directrices et conseils
À propos des lignes directrices

Systemic Therapy in Acute Lymphoblastic Leukemia

ID: 12-16 juin 2016
Type of Content: Guidelines & Advice, Evidence Summary
Document Status: Archived
Authors:
M. Sabloff, C. Agbassi, K. Howson-Jan, Systemic Treatment Disease Site Group

Guideline Objective

The objective of this evidence summary is to systematically review the available evidence with respect to the following two topics in the treatment of acute lymphoblastic/lymphocytic leukemia (ALL): - The use of pediatric-inspired regimens in the adolescent and young adult (AYA) population. - The use of tyrosine kinase inhibitors (TKIs) in adult patients with Philadelphia chromosome-positive (Ph+) ALL.

Patient Population

The purpose of this evidence summary is to inform care decisions regarding the use of ALL pediatric regimens in the treatment of AYAs with ALL.

Intended Guideline Users

This evidence summary is targeted for all people involved in systemic therapy treatment of patients with ALL.

Research Question(s)

  1. Compared with adult regimens, is there a benefit in the use of pediatric-inspired regimens for the management of non-pediatric patients with ALL?
  2. In the management of Ph+ ALL patients, does the addition of a TKI to the treatment regimen improve patient outcomes?
pdf download Full Report (PDF) (809.38 Ko)